Formulation Development
Lykan Bioscience & Vineti Announce Partnership to Advance Cell-Based Therapies From Clinical to Commercialization
Lykan Bioscience and Vineti recently announced a partnership to unite Lykan’s purpose-built cell therapy manufacturing capabilities and Vineti’s industry-leading….
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
DFE Pharma Demonstrates Impact of Powder Properties on the Rheological Behavior of Excipients
DFE Pharma, a global leader in pharmaceutical excipient solutions, is continuously supporting relevant scientific research and innovations in its field. With the recent publication of…
TriRx Hosted State & Community Leaders to Celebrate Acquisition of Shawnee, KS, Facility
TriRx Pharmaceutical Services, LLC, a leading international CDMO, hosted Kansas Lt. Governor David Toland, Shawnee Mayor Michelle Distler, State Senator Mike Thompson, Congresswoman Jo Ella…
Dotmatics to Deliver the Foundation for Croda’s R&D Digital Program: Artificial Intelligence & Data Mining
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, recently announced it has been selected….
VERAXA Biotech & Indivumed Cooperate on the Development of Precision Oncology Antibody
VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, recently announced their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for….
Daré Bioscience Announces FDA Acceptance & Priority Review of NDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. recently announced the US FDA accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial vaginosis…..
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of COVID-19 Infection & Associated Coagulopathy With rNAPc2
ARCA biopharma, Inc. recently announced it has submitted a Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications, for the use…
Catalent to Supply Edenbridge Pharmaceuticals With a Fast-Dissolve Zydis Formulation of Glycopyrrolate Intended as Adjunctive Therapy for Patients With Peptic Ulcer
Catalent recently announced it has signed a commercial supply agreement with Edenbridge Pharmaceuticals, LLC, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis orally…
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Aravive Inc. recently announced it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with…
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Study of FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. recently announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy…
Apollomics Doses First Patient in a Phase 1 Clinical Trial of APL-102
Apollomics Inc. recently announced the successful dosing of the first patient in a Phase 1 clinical study of APL-102 in patients with advanced solid tumors.…
Evonik Acquires JeNaCell to Expand Biomaterials Portfolio for New Medical Device Markets
Evonik has acquired German biotech company JeNaCell. The acquisition expands Evonik’s biomaterials portfolio to provide biotechnologically derived cellulose. The nature-identical material developed by….
DisperSol & Catalent Collaborate to Establish KinetiSol Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline
DisperSol Technologies and Catalent recently announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products…..
Carrick Therapeutics Announces Collaboration With Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
Carrick Therapeutics recently announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2-…
Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process
Pacira BioSciences, Inc. recently announced the US FDA has approved the company’s enhanced manufacturing process for EXPAREL (bupivacaine liposome injectable suspension) which is housed at…
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Mustang Bio, Inc. recently announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MB-107, its lentiviral gene therapy for the…
Croda Expands its High Purity Pharmaceutical Excipients Manufacturing Capability
Croda Inc. officially opened its newly expanded pharmaceutical excipients facility with a ribbon cutting celebration. The event, led by Mill Hall Site Director Robert Strouse,…
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every 6-Week Dosing With Natalizumab in Relapsing-Remitting Multiple Sclerosis
Biogen Inc. recently announced results from the 2-year prospective, randomized, interventional, controlled, open-label Phase 3b NOVA study (NCT03689972). NOVA was designed to estimate a potential…
